Rhino Biotech Limited (RBRXF)
OTHER OTC:RBRXF
US Market

Rhino Biotech Limited (RBRXF) Income Statement

0 Followers

Rhino Biotech Limited Income Statement

Last quarter (Q ), Rhino Biotech Limited's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Rhino Biotech Limited's net income was $-583.97K. See Rhino Biotech Limited’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 20Dec 19Dec 18Dec 17Dec 16
Total Revenue
-$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 814.69K$ 21.23K$ 20.42K$ 13.87K$ 22.84K$ 24.40K
Operating Income
$ -814.69K$ -21.23K$ -20.42K$ -13.87K$ -22.84K$ -24.40K
Net Non Operating Interest Income Expense
------
Other Income Expense
------
Pretax Income
-$ -21.23K$ -20.42K$ -13.87K$ -22.84K$ -24.40K
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -1.37M$ -21.23K$ -20.42K$ -13.87K$ -22.84K$ -24.40K
Basic EPS
$ -0.05$ >-0.01$ >-0.01$ >-0.01$ >-0.01$ >-0.01
Diluted EPS
$ -0.05$ >-0.01$ >-0.01$ >-0.01$ >-0.01$ >-0.01
Basic Average Shares
$ 86.38M$ 34.55M$ 34.55M$ 34.55M$ 34.55M$ 34.55M
Diluted Average Shares
$ 86.38M$ 34.55M$ 34.55M$ 34.55M$ 34.55M$ 34.55M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 814.69K$ 21.23K$ 20.42K$ 13.87K$ 22.84K$ 24.40K
Interest Expense
------
Net Income From Continuing And Discontinued Operation
$ -1.37M$ -21.23K$ -20.42K$ -13.87K$ -22.84K$ -24.40K
Normalized Income
$ -1.37M$ -21.23K$ -20.42K$ -13.87K$ -22.84K$ -24.40K
EBIT
$ -814.69K$ -21.23K$ -20.42K$ -13.87K$ -22.84K$ -24.40K
EBITDA
$ -799.39K$ -21.23K$ -20.42K$ -13.87K$ -22.84K$ -24.40K
Currency in USD

Rhino Biotech Limited Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis